1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Aerie Earnings Call August 8th, 2019

Discussion in 'Aerie Pharma' started by anonymous, Aug 7, 2019 at 4:54 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Based on the U.S. launch trajectory experience year-to-date in 2019, full-year 2019 net revenue guidance has been adjusted to a range of $70 million to $80 million from the previously reported range of $110 million to $120 million.

    Hmmm.
     

  2. anonymous

    anonymous Guest

    The man really compared Rocklatan to Combigan? Just stop it already.
     
  3. anonymous

    anonymous Guest

    They clearly do not understand the glaucoma market.
     
  4. anonymous

    anonymous Guest

    We MUST stay positive! Make that extra sales call each day!! Good Selling!
     
  5. anonymous

    anonymous Guest

    Can you elaborate?
     
  6. anonymous

    anonymous Guest

    Isn't it obvious?

    They missed the forecast by over one third

    If they knew the market these products they were in better they wouldn't have been that far off

    You seriously can't be that stupid
     
  7. anonymous

    anonymous Guest

    I didn't think the pressure could get turned any hire but I suppose the PIP machines are about to get cranked up to new record levels.
     
  8. anonymous

    anonymous Guest

    Your bad attitude is like a flat tire, you can't go anywhere until you fix it!!
     
  9. anonymous

    anonymous Guest

    Nero fiddled while Rome burned